These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20221663)

  • 1. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions.
    Nishimoto N; Ito K; Takagi N
    Mod Rheumatol; 2010 Jun; 20(3):222-32. PubMed ID: 20221663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J
    Ann Rheum Dis; 2009 Oct; 68(10):1580-4. PubMed ID: 19019888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Kivitz A; Olech E; Borofsky M; Zazueta BM; Navarro-Sarabia F; Radominski SC; Merrill JT; Rowell L; Nasmyth-Miller C; Bao M; Wright S; Pope JE
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1653-61. PubMed ID: 24942540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    An MM; Zou Z; Shen H; Zhang JD; Cao YB; Jiang YY
    Eur J Clin Pharmacol; 2010 Jan; 66(1):49-59. PubMed ID: 19936725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
    Patel AM; Moreland LW
    Drug Des Devel Ther; 2010 Oct; 4():263-78. PubMed ID: 21116333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
    Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
    Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
    Baek HJ; Lim MJ; Park W; Park SH; Shim SC; Yoo DH; Kim HA; Lee SK; Lee YJ; Park YE; Cha HS; Song YW
    Korean J Intern Med; 2019 Jul; 34(4):917-931. PubMed ID: 29334721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
    Emery P; Keystone E; Tony HP; Cantagrel A; van Vollenhoven R; Sanchez A; Alecock E; Lee J; Kremer J
    Ann Rheum Dis; 2008 Nov; 67(11):1516-23. PubMed ID: 18625622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
    Jones G; Sebba A; Gu J; Lowenstein MB; Calvo A; Gomez-Reino JJ; Siri DA; Tomsic M; Alecock E; Woodworth T; Genovese MC
    Ann Rheum Dis; 2010 Jan; 69(1):88-96. PubMed ID: 19297346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
    Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
    Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
    Navarro-Millán I; Singh JA; Curtis JR
    Clin Ther; 2012 Apr; 34(4):788-802.e3. PubMed ID: 22444783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
    Burmester GR; Feist E; Kellner H; Braun J; Iking-Konert C; Rubbert-Roth A
    Ann Rheum Dis; 2011 May; 70(5):755-9. PubMed ID: 21187298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
    Bouajina E; Zakraoui L; Kchir M; Kochbati S; Baklouti S
    Clin Rheumatol; 2020 May; 39(5):1449-1455. PubMed ID: 31838637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
    Navarro G; Taroumian S; Barroso N; Duan L; Furst D
    Semin Arthritis Rheum; 2014 Feb; 43(4):458-69. PubMed ID: 24262929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
    Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.
    Alfonso-Cristancho R; Armstrong N; Arjunji R; Riemsma R; Worthy G; Ganguly R; Kleijnen J
    Clin Rheumatol; 2017 Jan; 36(1):25-34. PubMed ID: 27726046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.